news
Leading dementia charity launches three Drug Discovery Institutes
18 February 2015 | By Alzheimer’s Research UK
Institutes at Universities of Cambridge, Oxford and UCL will form £30m Drug Discovery Alliance...
List view / Grid view
Hit-to-Lead
news
SensiQ Technologies and Inventiva set up a European Center of Excellence in surface plasmon resonance (SPR) technologies
9 February 2015 | By SensiQ Technologies/Inventiva
Based in Dijon, France, the Center will boast a unique offering for drug discovery in Europe, combining Inventiva’s screening platforms and libraries with SensiQ’s instrumentation...
news
Two major studies strengthen case for prostate cancer drug before chemotherapy
5 February 2015 | By The Institute of Cancer Research
Pioneering prostate cancer drug abiraterone significantly extends the lives of men with advanced prostate cancer if given before chemotherapy, the results of a major phase III clinical trial have shown...
news
Rigontec GmbH Appoints Dr. Christian Schetter as CEO
5 February 2015 | By Rigontec GmbH
Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the appointment of Dr. Christian Schetter as CEO...
news
Major study links two new genetic variants to breast cancer
5 February 2015 | By The Institute of Cancer Research
A worldwide study of the DNA of 100,000 women has discovered two new genetic variants associated with an increased risk of breast cancer...
news
Oncologic imaging innovation is enabling earlier detection of cancers
4 February 2015 | By Frost & Sullivan
Ongoing research aims to develop oncologic imaging technologies that diagnose cancer at the cellular level before the disease manifests, finds Frost & Sullivan...
news
Motif Bio announces intention to float on AIM
3 February 2015 | By Motif Bio
Motif Bio plc is seeking to raise at least £4 million through a placing of new ordinary shares and admission to trading on AIM...
news
First patient enrolled in the New Drugs 4 Bad Bugs (ND4BB) programme
3 February 2015 | By Innovative Medicines Initiative (IMI)
Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2 trial sponsored by MedImmune, the global biologics research and development arm of AstraZeneca. The trial with MEDI4893 is among mechanically ventilated intubated…
news
New Oncology and University Hospital Oslo announce genomic profiling collaboration
22 January 2015 | By B3C newswire
New Oncology and the University Hospital Oslo announced today that they have entered into a collaboration to identify alterations in cancer-related tumour genes that predict a patient’s response or resistance to targeted therapies...
news
Roche, Meiji and Fedora join forces to tackle increasing bacterial resistance to antibiotics
13 January 2015 | By Roche
Roche, Meiji Seika Pharma (Meiji) and Fedora announced that they have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development...
news
Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology
12 January 2015 | By Roche
Collaboration leverages both companies’ strengths to advance the progress of personalized treatments for patients with cancer...
news
Oxford Global Conferences received excellent feedback from the 2014 Drug Discovery USA Congress
8 January 2015 | By Oxford Global Conferences
Oxford Global Conferences were proud to present the Drug Discovery USA Congress this October in Boston, USA...
news
Trial finds cancer drug can block key signal in cancer growth and drug resistance
6 January 2015 | By The Institute of Cancer Research
An experimental cancer drug may block an important driver for the survival, growth and spread of cancer cells...
news
Key US patents granted for GPCR-focused drug discovery platform arising from pioneering research and translational expertise at MRC and MRC Technology
17 December 2014 | By MRC Technology
Structure-based drug discovery platform targets challenging GPCRs linked to human disease...
news
Midatech Pharma awarded EU grant funding to support training and research into glycan based multivalent immunotherapeutics
17 December 2014 | By Midatech Pharma
Midatech Pharma, a nanomedicine company developing and commercialising multiple therapeutic products to enhance the delivery of medicines in major diseases with high unmet medical needs, is pleased to announce that a consortium of academic and industry groups including Midatech has been awarded a €3.8 million European Union grant...
